Roche Holding AG
SIX:ROG
Roche Holding AG
Cash Equivalents
Roche Holding AG
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Roche Holding AG
SIX:ROG
|
Cash Equivalents
CHf5.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Novartis AG
SIX:NOVN
|
Cash Equivalents
$9.5B
|
CAGR 3-Years
36%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Cash Equivalents
$9m
|
CAGR 3-Years
244%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Cash Equivalents
$74m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Roche Holding AG's Cash Equivalents?
Cash Equivalents
5.4B
CHF
Based on the financial report for Dec 31, 2023, Roche Holding AG's Cash Equivalents amounts to 5.4B CHF.
What is Roche Holding AG's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
3%
Over the last year, the Cash Equivalents growth was 8%. The average annual Cash Equivalents growth rates for Roche Holding AG have been -2% over the past three years , -4% over the past five years , and 3% over the past ten years .